Syncom Formulations (India) Ltd - Stock Valuation and Financial Performance

BSE: 524470 | NSE: SYNCOMF | Pharmaceuticals & Drugs | Small Cap

Syncom Formulations Share Price

20.41 -0.71 -3.36%
as on 20-Dec'24 16:59

DeciZen - make an informed investing decision on Syncom Formulations

Overall Rating
Bole Toh

1. Quality

2. Valuation

Overvalued

3. Price Trend

Semi Strong

Syncom Formulations (India) stock performance -

mw4me loader
P/E Ratio (SA):
60.43
Market Cap:
1,918.5 Cr.
52-wk low:
10.6
52-wk high:
27.9

Is Syncom Formulations (India) Ltd an attractive stock to invest in?

1. Is Syncom Formulations (India) Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Syncom Formulations (India) Ltd is a average quality company.

2. Is Syncom Formulations (India) Ltd undervalued or overvalued?

The key valuation ratios of Syncom Formulations (India) Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Syncom Formulations (India) Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Syncom Formulations (India) Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Syncom Formulations:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Syncom Formulations (India) Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
ROCE % 15.6%14.7%13.6%9.4%9.4%12.4%20.7%10.6%9.7%10.5%-
Value Creation
Index
0.10.10.0-0.3-0.3-0.10.5-0.2-0.3-0.3-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 173184185159187206245220225258325
Sales YoY Gr.-6.1%0.5%-14.2%17.7%10%19.1%-10.3%2.3%15%-
Adj EPS 0.10.10.10.10.10.20.40.20.20.20.3
YoY Gr.-0%7.7%-21.4%27.3%28.6%100%-44.4%-10%33.3%-
BVPS (₹) 1.31.41.51.61.71.92.32.52.73.13.3
Adj Net
Profit
10.410.410.78.611.114.328.517.517.222.332
Cash Flow from Ops. 0.224.116.9-1.64.35.9-2.116.310.5-5.9-
Debt/CF from Ops. 32.50.20.7-7.820.4-30.13.57.9-12.1-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 4.5%6.7%1.8%15%
Adj EPS 7.1%11.4%-12.6%33.3%
BVPS10.1%12.4%10.7%12.1%
Share Price 11.6% 94.1% 29% 75.5%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
Return on
Equity %
10.6109.67.38.710.317.18.67.28.210.7
Op. Profit
Mgn %
10.59.18.97.46.38.215.59.18.910.911.7
Net Profit
Mgn %
65.75.85.55.9711.787.78.69.8
Debt to
Equity
0.10.10.10.10.100.40.30.30.30
Working Cap
Days
171181184186151142154240286230135
Cash Conv.
Cycle
2628255055617311111712095

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 10.70%

Sales growth is good in last 4 quarters at 34.68%

Sales growth has been subdued in last 3 years 1.81%

Net Profit has been subdued in last 3 years -12.64%

Latest Financials - Syncom Formulations (India) Ltd.

Standalone Consolidated
TTM EPS (₹) 0.3 0.4
TTM Sales (₹ Cr.) 325 329
BVPS (₹.) 3.3 3.3
Reserves (₹ Cr.) 211 220
P/BV 6.16 6.12
PE 60.43 57.88
From the Market
52 Week Low / High (₹) 10.60 / 27.94
All Time Low / High (₹) 0.14 / 27.94
Market Cap (₹ Cr.) 1,919
Equity (₹ Cr.) 94
Face Value (₹) 1
Industry PE 44.3

Management X-Ray of Syncom Formulations:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Syncom Formulations

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Sales173184185159187206245220225258
Operating Expenses 155167168147175189207200205230
Manufacturing Costs36303033344047414948
Material Costs8410710381107118120106101116
Employee Cost 13131415151618212434
Other Costs 21182218181521323033
Operating Profit 18171612121738202028
Operating Profit Margin (%) 10.5%9.1%8.9%7.4%6.3%8.2%15.5%9.1%8.9%10.9%
Other Income 2334557121513
Interest 0000010235
Depreciation 3334444455
Exceptional Items -1000000000
Profit Before Tax 16161612131741262732
Tax 66532312668
Profit After Tax 1010119111429202024
PAT Margin (%) 5.6%5.6%5.8%5.5%5.9%6.9%11.9%9.0%8.9%9.1%
Adjusted EPS (₹)0.10.10.10.10.10.20.40.20.20.3
Dividend Payout Ratio (%)16%15%15%0%0%0%0%0%14%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24

Equity and Liabilities

Shareholders Fund 100109114122133146178217256286
Share Capital 78787878787879869494
Reserves 22313644556899131162192
Minority Interest0000000000
Debt6612129262588372
Long Term Debt0000000000
Short Term Debt6612129262588372
Trade Payables20473222212029142014
Others Liabilities 16192017141622191719
Total Liabilities 142181179174176184292308377392

Fixed Assets

Gross Block80829298919395101102136
Accumulated Depreciation35373740434751545963
Net Fixed Assets46465558484644474372
CWIP 05010006260
Investments 623122111436466
Inventories11151011141623202121
Trade Receivables31464638414375687593
Cash Equivalents 767689640968
Others Assets4139595963697412513971
Total Assets 142181179174176184292308377392

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Cash Flow From Operating Activity 02417-246-21610-6
PBT 16161612131741262732
Adjustment 3100-1-1-2-7-6-3
Changes in Working Capital -12125-10-4-6-294-3-27
Tax Paid -6-5-4-3-3-4-11-6-7-8
Cash Flow From Investing Activity 1-23-8-222-75-27-4584
Capex 00-8-76-9-3-11-21-8
Net Investments 2-17-13-2-84-79-25-3878
Others -1-6126576101414
Cash Flow From Financing Activity 1-2-2-20-772835-15
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 0000000011
Interest Paid 0000000-1-3-4
Dividend Paid -2-2-2-20000-30
Others 2-1000-672940-12
Net Cash Flow 1-16-671-5-2163
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Ratios
ROE (%)9.999.919.567.338.7110.2418.0410.028.488.71
ROCE (%)15.5514.7213.589.439.3712.3920.7210.619.6810.46
Asset Turnover Ratio1.211.151.030.91.071.141.030.730.660.67
PAT to CFO Conversion(x)02.41.55-0.220.360.43-0.070.80.5-0.25
Working Capital Days
Receivable Days64769196777588118116119
Inventory Days22262524242629353330
Payable Days107115141123746475746254

Syncom Formulations (India) Ltd Stock News

Syncom Formulations (India) Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Syncom Formulations on 20-Dec-2024 16:59 is ₹20.41.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Dec-2024 16:59 the market cap of Syncom Formulations stood at ₹1,918.5.
The latest P/E ratio of Syncom Formulations as of 20-Dec-2024 16:59 is 60.43.
The latest P/B ratio of Syncom Formulations as of 20-Dec-2024 16:59 is 6.16.
The 52-week high of Syncom Formulations is ₹27.94 and the 52-week low is ₹10.60.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Syncom Formulations is ₹324.9 ( Cr.) .

About Syncom Formulations (India) Ltd

Syncom Formulations (India) Ltd was originally incorporated as Syncom Formulations (India) Private Limited in the state of Maharashtra on June 21, 1988 under the Companies Act, 1956. Further the status of company was changed to public limited company and thereby name of company changed to Syncom Formulations (India) Limited and a fresh certificate of change of name obtained on July 9, 1992.

The company was promoted by Kedarmal Bankda, Ajay Kumar Bankda & Vijay Kumar Bankda for manufacturing, marketing, dealership, importing, exporting & job work of pharmaceuticals, medicinal and other Industrial preparation & formulations under its own brands in ethical, OTC, generic and herbal market segment. The company came out with its Initial Public Offering in the Year 1994 hence obtained listing at BSE, DSE, ASE and MSE. However company has voluntarily de-listed its shares from ASE on July 8, 2004, MPSE on May 29, 2008 & DSE on September 2, 2004.

The company is engaged in the business of pharmaceutical formulations. It manufactures range of products in various dosage forms and markets them in various countries. In addition to pharmaceutical formulations in the form of tablets, capsules, liquids and dry powders, the company also manufactures Injectibles, inhalers and ear/eye drops. In 1994, the company undertook an expansion programme of setting up a new plant for manufacturing pharmaceutical formulations at Pithampur, Madhya Pradesh. The project which was financed through a public issue made in January 1994 was completed in 1995.

During the year 1997-98, the company has further diversified into ethical operations by introducing the range of prescription formulations. During the year 1998-99 there has been huge expansion of installed capacity and production base. Further the company introduced products in the generic, OTC and ethical divisions. During the year 2007-08 the company has further completed modernization and expansion of project in Pithampur unit, District Dhar, M.P with a total investment of Rs. 1516.62 Lakh.

Today, SFL stands as one of the fastest growing pharmaceutical company operating in more than 35 countries worldwide and has more than 150 products in various dosage forms which include tablets, capsules, dry syrups, and ointments/creams, dry powder Injections and ampoules and wide range of herbal products.

Syncom was keeping pace with the changing pharmaceutical scenario ventured into International market a decade ago. The International operations are managed from its International division located in Mumbai, commercial capital of India. Syncom today promotes all its generic, herbal and OTC range of products in the markets where it operates. Syncom's presence is felt in Asia, Africa, CIS, and Russia and Latin American countries. Mumbai Office also houses the Regulatory Affairs Department, which is well equipped with modern library, reference documents, and all other facilities to provide world-class registration dossiers.

Syncom's vision to globalise its herbal range of product has been vindicated by the excellent acceptance of these products by customers world over. Syncom has taken efforts to bring to mankind the goodness of AYURVEDA, the traditional Indian medicinal science through its unique range of herbal products used for various therapeutic and prophylactic purposes. Millions of healthy patients world wide, stand testimony to the alleviation of various disorders and improvement in their quality of life with products. The company presently exports goods to Guinea, Ghana, Kenya, Uganda, Sudan, Russia, Maldova, Tanzania, Africa, Azberjan, Nepal and Srilanka.

The company has been approved as a supplier to reputed hospitals and regulatory agencies including Central Medical Stores Organization of Gujarat Govt, Directorate of health services of Delhi Govt. and Central Govt. and supply to and registration of defense services is in its final stages. This results in generating substantial sales volume. Keeping in view the shifting consumer preferences for the use of herbal products, the company is aggressively manufacturing and marketing its herbal products like Colo Vaporex, Colo Inhaler, Edicare, Attom Megacaps, Ecziguard and Yas antacid salt.

In 2012 Company incorporated a Wholly Owned Subsidiary Company in the name of "TRADE ZONE FZE" in the United Arab Emirates.

Product range of the company includes:

Generic

  • Tablets
  • Capsules
  • Liquid Orals
  • Vials
  • Eye / Ear Drops
  • Ampoules
  • Dry Powder Orals

Herbal Branded

  • Colo Vaporex
  • Colo Inhaler
  • Colo Mouth Gel
  • Fastac Ointment
  • Candid Balm
  • Saloni Cream
  • Borosyn Cream
  • Edicare Cream
  • Ecziguard Cream
  • Pyl Gel
  • Attom Cream
  • Attom Megacaps
  • Shilajit Capsules
  • Liovset Tonic
  • Colo Cough Syrup
  • Pudin Rahat
  • Syncom Gripe Water
  • Feelax Powder
  • Yas Antacid Salt

Branded Allopathic

  • Qudermis Cream
  • Silver Plus Cream
  • Aciril Tablets
  • Fastac tablets
  • Odynil Tablets
  • Palera Plus Tablets
  • Polyfer Tablets 50 mg
  • Polyfer tablets 100 mg
  • Syncal D Tablets
  • M - Dox DT Tablets
  • Synortin Tablets
  • Synospas Tablets
  • Tici Forte Tablets
  • Triple Action Tablets
  • Flusa Kit Tablets
  • HBC kit (Combikit of 4 Tablets)
  • NTB-4 Kit Tablets
  • Fresca Tablets
  • Thixim
  • Thixim Tablets
  • Anergy Cap's
  • Grosyn
  • Profeed
  • Q-Coril Cough Formula
  • Syncal D-B12 Syrup
  • Aciril Suspension
  • Anergy Syrup
  • Nutone Syrup
  • Thixim-I Injection
  • Thixim-I Injection
  • Ceftacom Injection
  • Ceftacom Injection
  • TD-Mox
  • Polyfer Drops
  • Revive

Achievements/ recognition:

  • GMP certification
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.